EKF Diagnostics Holdings plc

If you would like to sign-up for EKF news and other Investor communications please email

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF expands geographical reach of PCT test for early sepsis detection

EKF brings niche Stanbio Chemistry Procalcitonin LiquiColor^® assay to new markets.

The prevalence of global diabetes is vastly underestimated, but new testing procedures could help

The prevalence of global diabetes has been seriously underestimated by at least 25 per cent, putting the global count at closer to 520 million people, instead of the 415 million figure previously estimated by the International Diabetes Federation (IDF) in 2015.

Visit EKF Diagnostics at MedLab Asia 2017

EKF Diagnostics, the global in vitro diagnostics company, will be highlighting many of its point-of-care (POC) and laboratory diagnostics products at MedLab Asia 2017, Singapore, 3 - 5 April.

New study reaffirms Quo-Test A1c meets IFCC performance criteria

EKF Diagnostics, the global in vitro diagnostics company, announces that in a newly published paper its Quo-Test^® point-of-care (POC) hemoglobin A1c (HbA1c) analyzer has again been confirmed to meet International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) performance criteria.

New Procalcitonin (PCT) study shows that testing reduces hospital costs and length of stay

A recent study published in CHEST found that the use of PCT screening on the first day of ICU admission was linked to significantly shorter hospital stays, as well as an overall decrease in cost of care.